Related Experiment Video

Updated: Jun 10, 2026

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience

James E Foley1, Jens Jordan

  • 1Clinical Research and Development, Novartis Pharmaceutical Corporation, East Hanover, NJ 07936, USA. james.foley@novartis.com

Vascular Health and Risk Management
|August 24, 2010
PubMed

Insights

Dipeptidyl peptidase-4 (DPP-4) inhibitors like vildagliptin are weight-neutral diabetes medications. Emerging research suggests vildagliptin may promote weight loss by inhibiting intestinal fat absorption and increasing fat oxidation.

Area of Science:

  • Endocrinology
  • Pharmacology
  • Metabolic Research

Background:

  • Diabetes medications have variable effects on patient weight.
  • Hypoglycemia-inducing agents and some other drug classes can cause weight gain.
  • Glucagon-like peptide-1 receptor agonists typically cause weight loss.

Purpose of the Study:

  • To explore the mechanisms behind the weight-neutral profile of dipeptidyl peptidase-4 (DPP-4) inhibitors, particularly vildagliptin.
  • To investigate potential novel pathways influencing vildagliptin's effect on body weight.
  • To clarify the origins of vildagliptin's favorable weight profile.

Main Methods:

  • Review of existing literature on diabetes medications and weight.
  • Analysis of studies examining vildagliptin's effects on lipid metabolism and energy expenditure.
  • Comparison of vildagliptin's effects with placebo in drug-naïve patients.

Main Results:

  • DPP-4 inhibitors are generally weight-neutral, with vildagliptin showing modest weight loss in some cases.
  • Vildagliptin demonstrated reduced chylomicron lipid and apolipoprotein levels, suggesting inhibited intestinal fat absorption.
  • Patients on vildagliptin showed increased postprandial fatty acid mobilization and oxidation, with enhanced sympathetic stimulation.

Conclusions:

  • Vildagliptin's weight neutrality may stem from its low risk of hypoglycemia.
  • Inhibition of intestinal fat extraction and promotion of fat oxidation are potential mechanisms for vildagliptin's favorable weight effects.
  • Further research into these pathways will elucidate vildagliptin's precise role in weight management for diabetes patients.
Keywords:
DPP-4 inhibitortype 2 diabetes mellitusvildagliptinweight

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...